Provided by Tiger Fintech (Singapore) Pte. Ltd.

Scienture Holdings, Inc.

1.59
-0.0500-3.05%
Post-market: 1.590.0001+0.01%19:35 EDT
Volume:96.02K
Turnover:153.53K
Market Cap:20.86M
PE:-0.57
High:1.67
Open:1.65
Low:1.56
Close:1.64
Loading ...

Scienture Holdings Inc. Enters into Indemnification Agreements with Key Directors and Officers

Reuters
·
04 Jul

Is Scienture Holdings (NASDAQ:SCNX) Using Debt Sensibly?

Simply Wall St.
·
03 Jul

Scienture announces cancellation of ELOC

TIPRANKS
·
17 Jun

Scienture Holdings Announces Cancelation of Eloc

THOMSON REUTERS
·
17 Jun

Scienture Holdings Inc - Continues to Expect to Launch Arbli in U.S. During Q3

THOMSON REUTERS
·
17 Jun

Scienture Appoints Co-CEOs as Suren Ajjarapu Steps Down

MT Newswires Live
·
22 May

Scienture Holdings Inc - Narasimhan Mani Appointed President and Co-CEO

THOMSON REUTERS
·
22 May

Scienture Holdings Inc - Suren Ajjarapu Steps Down as CEO and Chairman of Scienture

THOMSON REUTERS
·
22 May

Scienture Announces Executive Leadership Transition

THOMSON REUTERS
·
22 May

Scienture Holdings Inc - on May 16, Suren Ajjarapu Resigns as CEO and Chairman of Scienture Holdings - SEC Filing

THOMSON REUTERS
·
22 May

Scienture Holdings Inc - Appoints Narasimhan Mani and Shankar Hariharan as Co-Ceos - SEC Filing

THOMSON REUTERS
·
22 May

Scienture Holdings Inc. Faces Nasdaq Delisting Risk Over Minimum Bid Price Requirement

Reuters
·
22 May

Scienture announces FDA Orange Book patent listing for Arbli

TIPRANKS
·
19 May

Scienture Announces FDA Orange Book Patent Listing for Arblitm, (Losartanpotassium) Oral Suspension, 10Mg/Ml.

THOMSON REUTERS
·
19 May

BRIEF-Scienture Announces Manufacturing And Supply Chain Readiness For ArbliTM, (Losartan Potassium) Oral Suspension, 10Mg/Ml For A Target Product Launch In July 2025

Reuters
·
22 Apr

Scienture initiates supply chain activities by subsidiary to launch Arbli

TIPRANKS
·
22 Apr

SCIENTURE announces manufacturing and supply chain readiness for ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL for a target product launch in July 2025.

GlobeNewswire
·
22 Apr

Scienture Announces Manufacturing and Supply Chain Readiness for Arblitm, (Losartan Potassium) Oral Suspension, 10Mg/Ml for a Target Product Launch in July 2025.

THOMSON REUTERS
·
22 Apr

Scienture Sells 3 Subsidiaries to Tollo Health for $5 Million

MT Newswires Live
·
08 Apr

BRIEF-Scienture Announces The Divestiture Of Its Legacy Subsidiaries

Reuters
·
08 Apr